Cream could have been generating revenue by now if they didn't treat it like undifferentiated product and cancelled the idea of getting it on the shelfs.

The tablet trial is only for its delivery system and not actually for MM, unless I'm mistaken here.

The RS basically told us that company is broke, they f'd up on Toxic Lender and drew no interest from new investors, they want new interest but don't want to work for it.

Then they have around 20m in debt and no revenue, no IR or anything to bring in interest, toxic lender and bunch of old baggage trailing them, so even as minuscule 1m a day we cannot counter that while we still decline in SP.